Evidence mapPaperPMID 41367397Full record

ReviewFrontiers in physiology2025

Potential pathways for natural active ingredients to intervene in diabetic kidney disease: targeting macrophage infiltration.

Yan Yan, Wenru Wang, Yao Chen, Keqin Zhao, Tian Zhan, Xuemin Song, Jiayi Yang, Peng Liu, Renhuan Yu, Gang Wang

Abstract readReview
In one paragraph

Review in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yan Yan *Hubei University of Chinese Medicine, Wuhan, China.
Wenru Wang *Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Yao Chen *Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Keqin ZhaoXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Tian ZhanXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Xuemin SongHubei University of Chinese Medicine, Wuhan, China.
Jiayi YangXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Peng LiuXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Renhuan YuXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Gang WangDepartment of Nephrology, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease (DKD), a grave microvascular complication of diabetes, is the primary cause of end-stage renal disease. Despite advances in conventional therapies, their limited efficacy underscores the urgent need for novel, multi-target intervention strategies. Macrophage infiltration and the subsequent chronic microinflammation are central to the pathogenesis of renal injury in DKD. A diverse array of natural bioactive compounds are emerging as promising therapeutic agents, capable of modulating these inflammatory pathways. This review investigates the mechanisms underlying the attenuation of DKD progression by six major classes of natural compounds, such as glycosides, diterpenoids, and alkaloids, among others, through the targeting of macrophage infiltration. Collectively, this synthesis offers a compelling case for developing natural product-based, multiple-target strategies to combat DKD. Collectively, this synthesis builds a compelling case for developing multi-target therapeutic strategies derived from natural products to combat DKD.

Indexed as

active compoundsChinese herbal medicinediabetic kidney diseaseinflammationmacrophage infiltration

Identifiers

PMID41367397
PMCPMC12682673

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.